House Oversight and Reform Committee Chairman Elijah Cummings Elijah Eugene CummingsBlack GOP candidate accuses Behar of wearing black face in heated interview Overnight Health Care: US won't join global coronavirus vaccine initiative | Federal panel lays out initial priorities for COVID-19 vaccine distribution | NIH panel: 'Insufficient data' to show treatment touted by Trump works House Oversight Democrats to subpoena AbbVie in drug pricing probe MORE (D-Md.) on Wednesday accused ranking member Jim Jordan James (Jim) Daniel JordanHouse panel pulls Powell into partisan battles over pandemic Sunday shows preview: Justice Ginsburg dies, sparking partisan battle over vacancy before election House passes resolution condemning anti-Asian discrimination relating to coronavirus MORE (R-Ohio) of deliberately trying to undermine the committee’s investigation into rising drug prices.

In a letter sent Wednesday, Cummings condemned what he claimed were Jordan’s efforts to “actively obstruct” the committee’s investigation into prescription drug pricing.

ADVERTISEMENT

Cummings was responding to letters sent by Jordan and Rep. Mark Meadows Mark Randall MeadowsThe Hill's Morning Report - Sponsored by Facebook - GOP closes ranks to fill SCOTUS vacancy by November House moves toward spending vote after bipartisan talks House Democrats mull delay on spending bill vote MORE (R-N.C.) earlier this month, warning a dozen different drug company executives that Cummings was conducting a partisan investigation, essentially telling them not to participate.

“We hope to persuade Chairman Cummings to work with us on this matter but, in the interim, we felt that it was prudent to raise these issues with you directly,” Jordan and Meadows wrote to the industry executives.

The response from Cummings marks an escalation in his ongoing political battle with Jordan over the committee’s handling of sensitive information.

Jordan and Meadows in their letters indicated they were worried Cummings might decide to publicly release proprietary business information, even though it could harm the company's competitiveness.

Their letters to the drug companies specifically cited what they called Cummings’s unilateral decision to release excerpts of closed-door testimony from Tricia Newbold, a White House whistleblower who told the committee about alleged failures in the current security clearance process.

Cummings said the committee has been working for weeks on a protocol to protect sensitive documents obtained during an investigation, but Jordan has been blocking it.

“After spending weeks trying to consult with you and work with your staff on a bipartisan basis, it is difficult to view the claim in your letters” about wanting to work collaboratively “as anything but hypocritical,” Cummings wrote.

Cummings launched a sweeping investigation into the prescription drug industry’s pricing practices in January. He said companies have been cooperating with the review.

"It is one thing to have an honest disagreement about the Committee’s policy or approach — which would command respect — but it is quite another to actively obstruct an investigation in the service of placing corporate interests over those of the American people,” Cummings wrote.

Jordan’s letter accused Cummings of only being interested in bringing down drug company’s stock prices. Cummings said Jordan ignored his full comments about the committee’s impact, which he said were about saving taxpayers money.

In a statement to The Hill Wednesday, a spokesperson for Jordan said that "hurting private businesses will cost taxpayers more money" and that if Cummings really wants to save taxpayers money, "he should stop partisan investigations into the President, and actually start legislating."